Evidence map›Paper›PMID 41087189›Full record

ReviewZhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi2025

[Strategies for the diagnosis and treatment of pulmonary chronic graft-versus-host disease after hematopoietic stem cell transplantation].

C R Ju, S Q Wang, X Zhang, Q F Liu

Abstract readEnglish AbstractReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

C R JuDepartment of Organ Transplantation, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou Institute of Respiratory Health, National Center for Respiratory Medicine, National Center for Clinical Medical Research of Respiratory Diseases, State Key Laboratory of Respiratory Diseases, Guangzhou, 510120, China.
S Q WangGuangzhou First People's Hospital, Guangzhou, 510180, China.
X ZhangHematology Medical Center, The Second Affiliated Hospital of Army Medical University, Chongqing, 401147, China.
Q F LiuInstitute of Hematology, Southern Medical University, Guangzhou 510515, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hematopoietic stem cell transplantation (HSCT) is currently an effective method to cure hematologic malignancies and bone marrow failure diseases, and can restore hematopoietic function destroyed by hematologic malignant diseases. In recent years, HSCT has developed rapidly in China, but pulmonary chronic graft-versus-host disease after transplantation has seriously affected the quality of life and long-term survival of patients. Therefore, this article aims to describe the risk factors, clinical classification, and early diagnosis and treatment strategies of pulmonary chronic graft-versus-host disease, and proposes that lung transplantation is the only effective therapeutic intervention when medical treatment proves ineffective for end-stage pulmonary cGVHD.

Indexed as

Graft vs Host DiseaseHematopoietic Stem Cell TransplantationLung DiseasesChronic DiseaseHumans

Identifiers

PMID41087189
PMCPMC12541480

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.